KA/EN
Register
Medicines reference
Search
Search
Active substance

Telmisartan

Favourites

Angiotensin II receptor blocker. Registered in Georgia: 7 human medicines. Forms: solution, tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Telmisartan
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
1 mg/kg Cat Proteinuria in Chronic Kidney Disease By mouth once daily
VMD SPC 2023
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Telmitraxx 4 mg/ml oral solution for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2023
2 mg/kg Cat Systemic Hypertension By mouth once daily
IRIS 2026
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
IRIS Treatment Recommendations for Chronic Kidney Disease in Cats and in Dogs (2026)
IRIS, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use during pregnancy or lactation.
    Sources: VMD SPC · VMD
  • Critical
    Do not use during pregnancy or lactation.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical
    Do not give a RAAS inhibitor to a cat that is clinically dehydrated or shows signs of hypovolaemia. Restore hydration first.
    Sources: IRIS
  • Warning
    In cats with severe kidney disease, drugs acting on the RAAS can lower the glomerular filtration rate and worsen kidney function. The safety and efficacy of telmisartan in these cats have not been studied.
    Sources: VMD SPC · VMD · IRIS
  • Warning (Cat)
    The safety and efficacy of telmisartan has not been tested in cats under the age of 6 months.
    Sources: VMD SPC · VMD
  • Caution
    Elevated liver enzymes... Values normalised within a few days following cessation of therapy.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Major warning Benazepril + Telmisartan
    Available data in cats with CKD show no known interaction between telmisartan and other drugs acting on the RAAS (ARBs, ACE inhibitors), but combining drugs that act on the RAAS can change kidney function.
    Recommendation: Use an ACE inhibitor and an angiotensin-receptor blocker together only after an individual benefit-risk assessment. Monitor creatinine, potassium, blood pressure, and hydration closely so deterioration in renal function is detected promptly.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Telmisartan + Amlodipine
    During concomitant therapy with amlodipine at the recommended dose, no clinical evidence of hypotension was observed.
    Recommendation: Combine amlodipine and telmisartan only when either drug alone does not control blood pressure adequately. Measure blood pressure before treatment, correct dehydration, and recheck regularly after stabilisation.
    Sources: VMD SPC · VMD · IRIS
Latin name
Telmisartan
Georgian name
ტელმისარტანი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
7 of 8 forms
Products
Safetelmi, Telartan, Telmista, Telmitraxx, Telzisart
Human medicines in Georgia
Safetelmi, Telzisart
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration8

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Safetelmi 20 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.7/10
Situational / acceptable
vetman assessment

Safetelmi

20 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.7/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-036659 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 20 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality6.0/10

A validated half-tablet gives a 10 mg step, compatible with a 1 mg/kg starting dose only in some medium or large dogs; smaller patients and titration need a verified compounded liquid.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.9/10
Weak evidence support
vetman assessment

Safetelmi

20 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-036659 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 20 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality1.5/10

A half-tablet is 10 mg, still several times a typical cat dose. Ordinary subdivision cannot provide reliable feline dosing; use the authorised 4 mg/ml veterinary solution or a verified patient-specific compound.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan20 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
MSN Laboratories · India
Registration
Georgia Yes, human
In force until 21 Oct 2027
Human (Ministry of Health, RAMA)
In the register: საფეტელმი 20მგ აბი #30
№ რ-036659
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Safetelmi 40 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.4/10
Situational / acceptable
vetman assessment

Safetelmi

40 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-036660 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 40 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality4.5/10

The smallest recorded half-tablet is 20 mg, a coarse 20 kg dose step at 1 mg/kg. It can fit selected large dogs but is poor for smaller patients or response-guided titration without verified compounding.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.8/10
Weak evidence support
vetman assessment

Safetelmi

40 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-036660 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 40 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.5/10

A half-tablet is 20 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan40 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
MSN Laboratories · India
Registration
Georgia Yes, human
In force until 21 Oct 2027
Human (Ministry of Health, RAMA)
In the register: საფეტელმი 40მგ აბი #30
№ რ-036660
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Safetelmi 80 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.2/10
Situational / acceptable
vetman assessment

Safetelmi

80 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-036661 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 80 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality3.0/10

The smallest recorded half-tablet is 40 mg, a very coarse 40 kg dose step at 1 mg/kg. Direct use is limited to selected very large dogs; most patients require a lower strength or verified compounded liquid.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.7/10
Weak evidence support
vetman assessment

Safetelmi

80 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.7/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-036661 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 80 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.0/10

A half-tablet is 40 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan80 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
MSN Laboratories · India
Registration
Georgia Yes, human
In force until 21 Oct 2027
Human (Ministry of Health, RAMA)
In the register: საფეტელმი 80მგ აბი #30
№ რ-036661
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Telartan 80 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.2/10
Situational / acceptable
vetman assessment

Telartan

80 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-036774 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 80 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality3.0/10

The smallest recorded half-tablet is 40 mg, a very coarse 40 kg dose step at 1 mg/kg. Direct use is limited to selected very large dogs; most patients require a lower strength or verified compounded liquid.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.7/10
Weak evidence support
vetman assessment

Telartan

80 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.7/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-036774 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 80 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.0/10

A half-tablet is 40 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan80 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Edge Pharma
Registration
Georgia Yes, human
In force until 03 Nov 2027
Human (Ministry of Health, RAMA)
In the register: ტელარტანი 80მგ აბი #30
№ რ-036774
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Telmista 40 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.4/10
Situational / acceptable
vetman assessment

Telmista

40 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043128, რ-043129 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 40 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality4.5/10

The smallest recorded half-tablet is 20 mg, a coarse 20 kg dose step at 1 mg/kg. It can fit selected large dogs but is poor for smaller patients or response-guided titration without verified compounding.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.8/10
Weak evidence support
vetman assessment

Telmista

40 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043128, რ-043129 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 40 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.5/10

A half-tablet is 20 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan40 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 15 Apr 2030
Human (Ministry of Health, RAMA)
In the register: ტელმისტა 40მგ აბი #28, #84
№ რ-043128, რ-043129
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Telmista 80 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.2/10
Situational / acceptable
vetman assessment

Telmista

80 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043130, რ-043131 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 80 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality3.0/10

The smallest recorded half-tablet is 40 mg, a very coarse 40 kg dose step at 1 mg/kg. Direct use is limited to selected very large dogs; most patients require a lower strength or verified compounded liquid.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.7/10
Weak evidence support
vetman assessment

Telmista

80 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.7/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043130, რ-043131 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 80 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.0/10

A half-tablet is 40 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan80 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 15 Apr 2030
Human (Ministry of Health, RAMA)
In the register: ტელმისტა 80მგ აბი #28, #84
№ რ-043130, რ-043131
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Telmitraxx 4 mg/ml, Solution

oral solution for cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.4/10
Very good
vetman assessment

Telmitraxx

4 mg/ml, oral solution for cats
Assessed clinical scopeCat · Reduction of persistent renal proteinuria in an adequately hydrated, clinically stable cat with confirmed chronic kidney disease · By mouth
Care settingVeterinarian-directed chronic home treatment after CKD/proteinuria confirmation, with early and serial UPC, blood-pressure, renal-function and haematology monitoring
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: No · Verified on 22 Oct 2026

A very good, label-concordant once-daily veterinary option for persistent renal proteinuria in a stable hydrated cat with CKD. Exact generic equivalence, a large controlled feline trial and current consensus support the score; the benefit claim remains proteinuria reduction, with mandatory renal, blood-pressure and haematology monitoring.

Regulatory and scientific credibility8.5/10

Exact current veterinary product identity, SPC and GB/EU authorisations are public, and regulators accepted Telmitraxx as a generic of Semintra 4 mg/ml. The product is not registered in Georgia or the United States exact endpoint; the former US NADA match belonged to 10 mg/ml Semintra.

Clinical efficacy8.5/10

A 224-cat blinded multicentre randomised trial found telmisartan 1 mg/kg once daily noninferior to benazepril and significantly reduced UPC from baseline; current IRIS and iCatCare guidance supports the same role and dose. Evidence supports proteinuria reduction, not proven CKD reversal or survival prolongation.

Safety and tolerability8.0/10

Exact feline safety material and long clinical experience support good tolerability under correct selection. Dehydration/hypovolaemia, hypotension, severe renal dysfunction, reduced erythrocyte indices, pregnancy/lactation, gastrointestinal effects and concurrent RAAS inhibition remain meaningful labelled or consensus monitoring limits.

Clinical practicality9.0/10

The ready once-daily oral liquid, exact 0.25 ml/kg conversion, supplied syringe, direct-or-small-food administration and six-month in-use period are highly workable for chronic feline care. Accurate weighing, complete dose ingestion and serial monitoring are still required.

Full-course cost-effectiveness-

No verified current Georgian pack price, availability or patient-adjusted long-term course cost was found; foreign prices were not substituted.

Important safety and use flags

  • This score covers only reduction of persistent renal proteinuria in a stable, adequately hydrated cat with confirmed CKD. It does not cover unselected CKD, acute kidney injury, nonspecific renal support, dogs or systemic hypertension.
  • Do not substitute Semintra 10 mg/ml or its hypertension regimen. US NADA 141-501 is a different 10 mg/ml product dosed initially twice daily; Telmitraxx is 4 mg/ml and this assessment uses 1 mg/kg = 0.25 ml/kg once daily for CKD proteinuria.
  • Confirm persistent renal proteinuria and address pre-renal/post-renal causes, urinary sediment/infection and hypertension before attributing protein loss to CKD. Borderline UPC 0.2–0.4 usually requires monitoring rather than automatic treatment; current guidance treats persistent UPC >0.4.
  • Do not initiate in a clinically dehydrated or hypovolaemic cat. Correct volume status first because RAAS inhibition can precipitate a marked fall in glomerular filtration; acute or rapidly changing kidney disease is outside this rating.
  • Measure blood pressure, creatinine/renal markers, electrolytes, UPC and haematology at baseline and early after initiation, then serially. A small stable creatinine rise can occur; marked or progressive azotaemia, hypotension, weakness, anorexia or dehydration requires prompt reassessment.
  • Do not combine with another ACE inhibitor or angiotensin-receptor blocker as routine therapy. Other antihypertensive or diuretic treatment can amplify hypotension or renal effects; document the combination rationale and monitor closely.
  • Do not use during pregnancy or lactation. Safety is not established in breeding cats or kittens under six months; pregnant people should avoid exposure to RAAS-active solutions and wash skin immediately after accidental contact.
  • Stop and reassess for persistent vomiting/regurgitation, diarrhoea, reduced appetite, weight loss, lethargy, hypersensitivity or liver-enzyme elevation. Reduced erythrocyte indices are a known class/product monitoring issue rather than a reason to omit baseline haematology.
  • Use the supplied syringe and current body weight. Give directly into the mouth or with only a small amount of food and confirm the whole dose is consumed; do not hide it in a full meal. Avoid contaminating the syringe or bottle opening.
  • Store below 30°C in the original container and use within six months after opening. Record the opening date. Georgian registration and current local availability are absent, so procurement and replacement continuity must be confirmed before starting long-term therapy.
Assessment sources
  1. Telmitraxx current SPC2026
  2. Telmitraxx VMD product record2026
  3. Telmitraxx public assessment2023
  4. Telmitraxx EU authorisation2026
  5. Semintra 4 mg/ml reference product2026
  6. Telmisartan-benazepril feline trial2015
  7. IRIS CKD 20262026
  8. iCatCare feline CKD 20262026
  9. FDA Semintra 10 mg/ml label2019
  10. GE telmisartan veterinary audit2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan4 mg/ml
Formulation Type
Solution
Administration route
By mouth
Manufacturer
Alfasan Nederland B.V. · Netherlands
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ NL/V/0386/001
Verified on: 22 Oct 2026
 UK Yes, veterinary
№ Vm 36408/5016
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Labelled feline CKD-proteinuria dose: 1 mg telmisartan/kg (0.25 ml/kg) PO once daily, directly into the mouth or with a small amount of food, using the supplied syringe. This is not the 10 mg/ml feline-hypertension product or regimen. Confirm persistent renal proteinuria in stable CKD, correct dehydration first and monitor UPC, blood pressure, renal function and erythrocytes.

Telzisart 40 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.4/10
Situational / acceptable
vetman assessment

Telzisart

40 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-037851 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 40 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality4.5/10

The smallest recorded half-tablet is 20 mg, a coarse 20 kg dose step at 1 mg/kg. It can fit selected large dogs but is poor for smaller patients or response-guided titration without verified compounding.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.8/10
Weak evidence support
vetman assessment

Telzisart

40 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-037851 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 40 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.5/10

A half-tablet is 20 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan40 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Zim Laboratories · India
Registration
Georgia Yes, human
In force until 11 Apr 2028
Human (Ministry of Health, RAMA)
In the register: ტელზისარტი 40მგ აბი #30
№ რ-037851
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗